Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Shanghai Haohai Biological Technology Co., Ltd.\*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 6826)

## **POSITIVE PROFIT ALERT**

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd. (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company ("**Shareholders**") and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six-month period ended 30 June 2015, it is expected that the Group would record the following increases in its unaudited revenue and consolidated profit attributable to the equity holders of the Company:

- 1. an increase of over 30% in revenue for the six-month period ended 30 June 2015 as compared to the Group's revenue for the corresponding period in 2014; and
- 2. an increase of over 70% in unaudited consolidated profit attributable to equity holders of the Company for the six-month period ended 30 June 2015 as compared to the Group's profit attributable to the equity holders of the Company for the corresponding period in 2014; and after excluding one-off realized foreign exchange gain from the proceeds of the Company's listing in April 2015, an increase of over 40% in unaudited consolidated profit attributable to equity holders of the Company for the six-month period ended 30 June 2015 as compared to the Group's profit attributable to the equity holders of the Company for the six-month period ended 30 June 2015 as compared to the Group's profit attributable to the equity holders of the Company for the corresponding period in 2014.

The increases in revenue and profit as described above are mainly attributable to (i) the consistent growth in the sales of the sodium hyaluronate injection signature product of the Group, and (ii) the rapid growth in the sales of certain products of the Group launched in recent years, namely medical chitosan products for intra-articular injection and Matrifill<sup>®</sup> branded dermal filler products, leading to an increase in the market share of the Group in the result.

The information set out in this announcement is only based on the information currently available to the Company and the Board's preliminary assessment of the unaudited consolidated management accounts of the Group for the six-month period ended 30 June 2015, which is subject to finalization and other potential adjustments (if necessary) and is not based on any figures or information audited or reviewed by the Company's auditors. Shareholders and potential investors are advised to read carefully the unaudited interim results announcement of the Group for the six-month period ended 30 June 2015, which is expected to be published in late August 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Shanghai Haohai Biological Technology Co., Ltd. Chairman Hou Yongtai

Shanghai, PRC, 13 August 2015

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Ling Xihua, Mr. Huang Ping and Ms. Chen Yiyi; the non-executive directors of the Company are Ms. You Jie and Mr. Gan Renbao; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Li Yuanxu, Mr. Zhu Qin and Mr. Wong Kwan Kit.

\* For identification purpose only